



Board Communiqué

The Board approves a VCU in the Risperdal Consta matter

OTTAWA, June 7, 2007: The Patented Medicine Prices Review Board ("Board") approved a Voluntary Compliance Undertaking ("VCU") agreed to by Janssen-Ortho Inc. and Board Staff to, among others, reduce of the price of Risperdal Consta to a non-excessive level and the offset of excess revenues in the amount of \$4,386,172.99.

The Board issued a Notice of Hearing on January 30, 2007, pertaining to the allegations of Board Staff that Risperdal Consta had been, and was being, sold by Janssen-Ortho at prices exceeding the Excessive Price Guidelines. The Board commenced its hearing in this matter on June 7, 2006. On June 1, 2007, the Board received a submission for the approval of a VCU to resolve all issues raised by the Notice of Hearing.

By Order of the Board, the proceeding that was commenced by the issuance of Notice of Hearing on January 30, 2006, is hereby concluded.

Risperdal Consta is a new formulation of an existing compound (risperidone) indicated for the management of the manifestations of schizophrenia and related psychotic disorders.

The Board's Order is a public document and is available on the PMPRB Web site under Regulatory; Hearings; **Risperdal Consta**, or by contacting the Secretary of the Board.

Sylvie Dupont
Secretary of the Patented Medicine Prices Review Board
Toll-free #: 1 877 861-2350; Direct line: (613) 954-8299
E-mail address: sdupont@pmprb-cepmb.gc.ca